{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Steven J Edwards, Charlotta Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk, Zenas Z N Yiu & Miriam Wittmann.

Steven J Edwards ^1,*, Charlotta Karner ², Tracey Jhita ³, Samantha Barton ⁴, Gemma Marceniuk ⁵, Zenas Z N Yiu ⁶, Miriam Wittmann ⁷

¹ Director of Health Technology Assessment, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK
² Clinical Evidence Manager, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK
³ Health Economics Manager, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK
⁴ Principal Clinical Evidence Analyst, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK
⁵ Senior Health Economist, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK
⁶ NIHR Clinical Lecturer in Dermatology, University of Manchester, Manchester, UK
⁷ Associate Professor in Inflammatory Skin Diseases, University of Leeds, Leeds, UK
^* Corresponding author Email: sedwards@bmj.com

Disclosure of interests

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at https://doi.org/10.3310/LEXB9006.

Primary conflicts of interest: No competing interests were declared by Steven J Edwards, Charlotte Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk or Zenas Z N Yiu which affect the impartiality of this report. BMJ Technology Assessment Group (BMJ-TAG) and the editorial team of the BMJ work independently to one another. The views and opinions expressed in this report are those of the BMJ-TAG. In the past 36 months, Miriam Wittmann has received research grants from AbbVie, the British Skin Foundation, Janssen, Lupus UK, Novartis, Pfizer Global and UCB. MW has received a consultancy fee from UCB for acting on an advisory board, and remuneration from various companies for carrying out educational lectures.

Rider on responsibility for report: The views expressed in this report are those of the authors and not necessarily those of the NIHR Evidence Synthesis Programme. Any errors are the responsibility of the authors.

Report reference: Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu Z, Wittmann M. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. BMJ Technology Assessment Group; 2021.